Gilead Sciences (GILD) Reports Q2: Everything You Need To Know Ahead Of Earnings

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after market close. Here’s what investors should know.

Gilead Sciences missed analysts’ revenue expectations by 2.1% last quarter, reporting revenues of $6.67 billion, flat year on year. It was a softer quarter for the company, with full-year revenue guidance slightly missing analysts’ expectations.

Is Gilead Sciences a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Gilead Sciences’s revenue to be flat year on year at $7.00 billion, slowing from the 5.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.96 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Gilead Sciences has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 3.3% on average.

Looking at Gilead Sciences’s peers in the therapeutics segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 7.3%, beating analysts’ expectations by 13.7%, and Myriad Genetics reported flat revenue, topping estimates by 5.5%. Biogen traded up 3.9% following the results.

Read our full analysis of Biogen’s results here and Myriad Genetics’s results here.

Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the therapeutics stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Gilead Sciences’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $118.16 (compared to the current share price of $112.50).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.